suggest that treatment with DA may be discontinued after menopause in microprolactinoma because of two reasons, the first being the lack of evidence of harmful effects of hyperprolactinemia on health other than on gonadotropic function, especially since there are no convincing epidemiological studies in favor of an association between hyperprolactinemia and breast cancer, and the second being spontaneous gradual normalization commonly seen in PRL levels after menopause, 44% of cases in one study (7,23). The gene discussed is PRL; the disease is hyperprolactinemia.